Janssen's Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma
Shots:
- The approval is based on P-III MAIA study assessing Darzalex + lenalidomide + dexamethasone (Rd) vs Rd as monothx. in 737 patients with newly diagnosed multiple myeloma who are ineligible for high-dose chemotherapy and ASCT aged 45-90 yrs.
- The P-III MAIA study results: 44% reduction in risk of disease progression; CR (48% vs 25%); PR (79% vs 53%); ORR (93% vs 81%); patients achieving CR & better MRD negativity status (10-5) (24% vs 7%); @median-follow up of 28mos. mPFS (not reached vs 31.9mos.)
- Darzalex is a CD38-directed antibody and is an approved therapy as monothx. or in combination with other drugs in multiple countries including the US for the treatment of multiple myeloma. In Aug’2012- Genmab granted exclusive rights of Darzalex to Janssen
Click here to read full press release/ article
Ref: Newswire Canada | Image: Janssen
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com